|Amgen Inc -- USA Stock|| |
USD 183.55 0.05 0.0272%
Mr. Fred Hassan is Director of Amgen Inc. Mr. Fred Hassan was Partner and Managing Director at Warburg Pincus LLC, a global private equity investment institution, since 2011 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of ScheringPlough Corporationrationration from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of Pharmacia Corporationrationration, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of Pharmacia Corporationrationration from its creation in 2000 as a result of the merger of Pharmacia Upjohn, Inc. with Monsanto Company. He was President and Chief Executive Officer of Pharmacia Upjohn, Inc. beginning in 1997. Mr. Hassan previously held senior positions with Wyeth, including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at Sandoz Pharmaceuticals and headed its U.S. pharmaceuticals businesses.
Age: 70 Director Since 2015
The company has return on total asset (ROA)
of 8.32 %
which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 7.18 %
meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.